WHAT IS HYRNUO?

HYRNUO® is an oral treatment for adults with a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC) that has spread within the chest (locally advanced) or to other parts of the body (metastatic) and has a certain abnormal HER2 gene(s).*

HYRNUO is approved under accelerated approval based on patient response data and duration of response. Studies are ongoing to confirm the clinical benefit of HYRNUO.

*HER2 is sometimes referred to as ERBB2 (erb-b2 receptor tyrosine kinase 2). HER2 stands for human epidermal growth factor receptor 2.

HYRNUO TARGETS AND BLOCKS HER2 MUTATIONS

Illustration of cancer cell growth signals being blocked

HYRNUO works by targeting receptors on cells that signal growth, including cancer cells with mutated HER2.† These mutations can lead to signals that promote uncontrolled and rapid growth of cancer cells. HYRNUO is designed to block these signals, which may help slow or stop the growth of cancer cells.

HYRNUO is not chemotherapy, it is a treatment called a tyrosine kinase inhibitor (TKI).‡

†A mutation is an abnormal change in a gene. The gene is the basic unit of heredity passed down from parent to child. Genes are made up of DNA.

‡A TKI is a targeted therapy that inhibits cancer cell growth.

DNA=deoxyribonucleic acid.

RESOURCES ARE AVAILABLE FOR HYRNUO PATIENTS